OM:BIOT - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,671	469	631	766	3
12/31/2025	2,380	361	419	546	3
12/31/2024	2,110	262	302	420	3
3/31/2024	1,981	236	268	381	N/A
12/31/2023	1,862	246	193	284	N/A
9/30/2023	1,603	189	183	264	N/A
6/30/2023	1,555	216	182	258	N/A
3/31/2023	1,541	240	220	295	N/A
12/31/2022	1,566	268	271	341	N/A
9/30/2022	1,524	240	285	346	N/A
6/30/2022	1,428	228	285	338	N/A
3/31/2022	1,337	216	290	342	N/A
12/31/2021	1,232	205	297	353	N/A
9/30/2021	1,188	203	273	336	N/A
6/30/2021	1,145	187	256	321	N/A
3/31/2021	1,096	174	222	286	N/A
12/31/2020	1,092	175	218	279	N/A
9/30/2020	1,083	149	213	268	N/A
6/30/2020	1,103	179	221	274	N/A
3/31/2020	1,131	201	211	260	N/A
12/31/2019	1,101	187	166	212	N/A
9/30/2019	1,047	196	145	187	N/A
6/30/2019	997	173	112	158	N/A
3/31/2019	951	170	94	139	N/A
12/31/2018	911	168	108	155	N/A
9/30/2018	865	175	120	170	N/A
6/30/2018	811	162	104	149	N/A
3/31/2018	771	148	123	168	N/A
12/31/2017	748	139	N/A	169	N/A
9/30/2017	738	122	N/A	145	N/A
6/30/2017	728	118	N/A	145	N/A
3/31/2017	694	105	N/A	131	N/A
12/31/2016	668	93	N/A	139	N/A
9/30/2016	657	96	N/A	130	N/A
6/30/2016	640	87	N/A	133	N/A
3/31/2016	625	78	N/A	133	N/A
12/31/2015	611	73	N/A	120	N/A
9/30/2015	580	83	N/A	116	N/A
6/30/2015	549	75	N/A	98	N/A
3/31/2015	521	75	N/A	94	N/A
12/31/2014	490	65	N/A	81	N/A
9/30/2014	474	53	N/A	72	N/A
6/30/2014	459	49	N/A	70	N/A
3/31/2014	455	46	N/A	52	N/A
12/31/2013	445	41	N/A	57	N/A
9/30/2013	437	37	N/A	66	N/A
6/30/2013	441	33	N/A	64	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BIOTの予測収益成長率 (年間20% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: BIOTの収益 ( 20% ) はSwedish市場 ( 14.1% ) よりも速いペースで成長すると予測されています。

高成長収益: BIOTの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: BIOTの収益 ( 11.1% ) Swedish市場 ( 1.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: BIOTの収益 ( 11.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIOTの自己資本利益率は、3年後には低くなると予測されています ( 10.2 %)。

Biotage 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 9.6% to kr190

Price target decreased by 7.1% to kr173

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Price target decreased by 7.1% to kr173

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Price target increased by 9.6% to kr190

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Price target decreased by 7.1% to kr173

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage AB (Publ) Approves a Dividend, Payable on May 3, 2024

Upcoming dividend of kr1.60 per share

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to kr173

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Dividend of kr1.60 announced

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 23%

Biotage Appoints Andrew Kellett as CFO

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Now 23% overvalued after recent price rise

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Now 22% undervalued

Biotage AB (publ) Announces CEO Changes

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Third quarter 2023 earnings: Revenues in line with analyst expectations

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Consensus EPS estimates fall by 26%

Biotage AB (Publ) Announces Executive Changes

New minor risk - Insider selling

Insider recently sold kr675k worth of stock

Biotage AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Second quarter 2023 earnings: Revenues exceed analyst expectations

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 26%

Price target decreased by 29% to kr180

Now 23% undervalued

New minor risk - Shareholder dilution

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Investor sentiment improves as stock rises 24%

Director recently bought kr2.0m worth of stock

Upcoming dividend of kr1.60 per share at 1.3% yield

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Price target decreased by 12% to kr212

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Consensus EPS estimates fall by 17%, revenue upgraded

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Biotage AB (Publ) Proposes Dividend for 2022

Full year 2022 earnings released: EPS: kr4.06 (vs kr3.14 in FY 2021)

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

No independent directors

Third quarter 2022 earnings: Revenues exceed analyst expectations

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Biotage AB (publ) Appoints Nomination Committee

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Biotage (STO:BIOT) Could Easily Take On More Debt

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Price target decreased to kr242

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?